Outcomes of mitral valve surgery for severe ischemic mitral regurgitation.
clinical review
coronary artery disease
valve repair/replacement
Journal
Journal of cardiac surgery
ISSN: 1540-8191
Titre abrégé: J Card Surg
Pays: United States
ID NLM: 8908809
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
pubmed:
11
12
2019
medline:
1
9
2020
entrez:
11
12
2019
Statut:
ppublish
Résumé
This study evaluated outcomes of mitral valve surgery for severe ischemic mitral regurgitation (IMR). Patients undergoing coronary artery bypass grafting (CABG) with concomitant mitral valve repair (MVr) or replacement (MVR) for severe IMR at a single center between 2010 and 2017 were included. The primary outcome was 5-year survival. Secondary outcomes included operative mortality and morbidity, hospital readmission, recurrence of at least moderate mitral regurgitation (MR), and mitral valve reoperation. A total of 358 patients underwent concomitant mitral valve surgery with CABG for severe IMR (275 MVr and 83 MVR). Unadjusted and risk-adjusted operative mortality was higher in MVR (16% vs 8%; P = .04). MVR patients had higher rates of postoperative renal failure, prolonged ventilation, and deep sternal wound infection. The unadjusted 5-year survival was similar (MVR 64% vs MVr 64%; P = .41), a finding that persisted after risk-adjustment. The 5-year freedom from mitral valve reoperation was 96% and 97% (P = .47). Freedom from at least moderate MR at 1-year and 3-years was 100% vs 86% (P = .09) and 100% vs 68% (P = .06) for MVR and MVr, respectively. However, only three MVr patients developed severe MR by 3 years. Cumulative hazards for all-cause readmission and heart failure-specific readmission were higher with MVR. Despite a trend towards higher risk of MR recurrence, patients undergoing MVr have similar rates of survival and mitral valve reoperation, with lower rates of readmission at 5-years. This, combined with lower operative mortality rates, makes MVr a reasonable choice particularly in sicker patients with higher operative risk and more limited life expectancy.
Sections du résumé
BACKGROUND
BACKGROUND
This study evaluated outcomes of mitral valve surgery for severe ischemic mitral regurgitation (IMR).
METHODS
METHODS
Patients undergoing coronary artery bypass grafting (CABG) with concomitant mitral valve repair (MVr) or replacement (MVR) for severe IMR at a single center between 2010 and 2017 were included. The primary outcome was 5-year survival. Secondary outcomes included operative mortality and morbidity, hospital readmission, recurrence of at least moderate mitral regurgitation (MR), and mitral valve reoperation.
RESULTS
RESULTS
A total of 358 patients underwent concomitant mitral valve surgery with CABG for severe IMR (275 MVr and 83 MVR). Unadjusted and risk-adjusted operative mortality was higher in MVR (16% vs 8%; P = .04). MVR patients had higher rates of postoperative renal failure, prolonged ventilation, and deep sternal wound infection. The unadjusted 5-year survival was similar (MVR 64% vs MVr 64%; P = .41), a finding that persisted after risk-adjustment. The 5-year freedom from mitral valve reoperation was 96% and 97% (P = .47). Freedom from at least moderate MR at 1-year and 3-years was 100% vs 86% (P = .09) and 100% vs 68% (P = .06) for MVR and MVr, respectively. However, only three MVr patients developed severe MR by 3 years. Cumulative hazards for all-cause readmission and heart failure-specific readmission were higher with MVR.
CONCLUSIONS
CONCLUSIONS
Despite a trend towards higher risk of MR recurrence, patients undergoing MVr have similar rates of survival and mitral valve reoperation, with lower rates of readmission at 5-years. This, combined with lower operative mortality rates, makes MVr a reasonable choice particularly in sicker patients with higher operative risk and more limited life expectancy.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
390-396Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
Varma P, Krishna N, Jose R, Madkaiker A. Ischemic mitral regurgitation. Ann Card Anaesth. 2017;20(4):432.
Bursi F, Enriquez-Sarano M, Nkomo VT, et al. Heart failure and death after myocardial infarction in the community. Circulation. 2005;111(3):295-301.
Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2015 update. Circulation. 2015;131(4):e29-e322.
Trochu J-N, Dillon R, Gustafsson F, Mitchell SA, Mitrovic V, Alfieri O. Mitral regurgitation-unmet need for improved management strategies. Int J Cardiol Hear Vasc. 2014;5:26-41.
Calafiore AM, Di Mauro M, Gallina S, et al. Mitral valve surgery for chronic ischemic mitral regurgitation. Ann Thorac Surg. 2004;77:1989-1997.
Al-Radi OO, Austin PC, Tu JV, David TE, Yau TM. Mitral repair versus replacement for ischemic mitral regurgitation. Ann Thorac Surg. 2005;79:1260-1267.
Micovic S, Milacic P, Otasevic P, et al. Comparison of valve annuloplasty and replacement for ischemic mitral valve incompetence. Heart Surg Forum. 2008;11:E340-E345.
Qiu Z, Chen X, Xu M, et al. Is mitral valve repair superior to replacement for chronic ischemic mitral regurgitation with left ventricular dysfunction? J Cardiothorac Surg. 2010;5:107.
Chan V, Ruel M, Mesana TG. Mitral valve replacement is a viable alternative to mitral valve repair for ischemic mitral regurgitation: a case-matched study. Ann Thorac Surg. 2011;92:1358-1365.
De Bonis M, Ferrara D, Taramasso M, et al. Mitral replacement or repair for functional mitral regurgitation in dilated and ischemic cardiomyopathy: is it really the same? Ann Thorac Surg. 2012;94:44-51.
Goldstein D, Moskowitz AJ, Gelijns AC, et al. Two-year outcomes of surgical treatment of severe ischemic mitral regurgitation. N Engl J Med. 2016;374(4):344-353.
Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation. 2014;129:2440-2492.
Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation. 2017;135(25):e1159-e1195.
Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81(3):515-526.
D'Agostino RS, Jacobs JP, Badhwar V, et al. The Society of Thoracic Surgeons Adult Cardiac Surgery Database: 2018 update on outcomes and quality. Ann Thorac Surg. 2018;105(1):15-23.
Gammie JS, Sheng S, Griffith BP, et al. Trends in mitral valve surgery in the United States: results from the Society of Thoracic Surgeons Adult Cardiac Surgery Database. Ann Thorac Surg. 2009;87(5):1431-1437.
Al-Sarraf N, Thalib L, Hughes A, et al. Cross-clamp time is an independent predictor of mortality and morbidity in low- and high-risk cardiac patients. Int J Surg. 2011;9(1):104-109.
Vassileva CM, Ghazanfari N, Spertus J, McNeely C, Markwell S, Hazelrigg S. Heart failure readmission after mitral valve repair and replacement: five-year follow-up in the Medicare population. Ann Thorac Surg. 2014;98(5):1544-1550.
Kron IL, Hung J, Overbey JR, et al. Predicting recurrent mitral regurgitation after mitral valve repair for severe ischemic mitral regurgitation. J Thorac Cardiovasc Surg. 2015;149(3):752-761.
Bouma W, Lai EK, Levack MM, et al. Preoperative three-dimensional valve analysis predicts recurrent ischemic mitral regurgitation after mitral annuloplasty. Ann Thorac Surg. 2016;101(2):567-575.
Nappi F, Lusini M, Spadaccio C, et al. Papillary muscle approximation versus restrictive annuloplasty alone for severe ischemic mitral regurgitation. J Am Coll Cardiol. 2016;67(20):2334-2346.
Suri RM, Clavel MA, Schaff HV, et al. Effect of recurrent mitral regurgitation following degenerative mitral valve repair: long-term analysis of competing outcomes. J Am Coll Cardiol. 2016;67(5):488-498.
Kim JH, Lee SH, Joo HC, et al. Effect of recurrent mitral regurgitation after mitral valve repair in patients with degenerative mitral regurgitation. Circ J. 2017;82(1):93-101.
Maltais S, Schaff HV, Daly RC, et al. Mitral regurgitation surgery in patients with ischemic cardiomyopathy and ischemic mitral regurgitation: factors that influence survival. J Thorac Cardiovasc Surg. 2011;142(5):995-1001.
Bax JJ, Braun J, Somer ST, et al. Restrictive annuloplasty and coronary revascularization in ischemic mitral regurgitation results in reverse left ventricular remodeling. Circulation. 2004;110(11 suppl 1):II103-II108.
Ciarka A, Braun J, Delgado V, et al. Predictors of mitral regurgitation in patients with heart failure undergoing mitral valve annuloplasty. Am J Cardiol. 2010;106(3):395-401.